19. Brain metastases

Background
This is a heterogeneous population of patients with diverse underlying histologies, differences in disease burden outside the central nervous system (CNS) and differing systemic therapy options. As such, it is helpful to classify patients according to a simplified system. The original recursive partitioning analysis (RPA) based system of the Radiation Therapy Oncology Group (RTOG) is simple and robust, but has now been replaced by the Graded Prognostic Assessment (GPA) and the disease-specific GPA (dsGPA). These prognostic scores continue to evolve, and still do not fully reflect the latest systemic therapies.

Patients can be divided into three groups according to disease specific factors, but in general these three of importance:

- Karnofsky Performance Status (KPS) (at least 70)
- Control of the primary tumour
- Brain as the only site of disease.

Patients who fail to meet all three criteria tend to have a very poor prognosis, and may not benefit from treatment.

The regimens most commonly used for the whole-brain radiotherapy (WBRT) treatment of cerebral metastases are 30 Gy in ten fractions over two weeks or 20 Gy in five fractions over one week. For patients with limited disease, other approaches, including gamma knife or stereotactic radiosurgery (SRS) and intraoperative radiotherapy are feasible. The following discussion draws heavily on a systematic review performed as part of the Cancer Care Ontario programme in evidence-based care.

Solitary or oligo-metastases

The evidence from one systematic review and three randomised trials suggests benefit from adding surgery to whole brain radiotherapy (WBRT) for patients of good performance status with a solitary metastasis (Level 1a). Stereotactic radiosurgery (SRS) added to WBRT offers a survival benefit for selected patients with a solitary metastasis, as well as for patients of RPA Class I with up to three metastases. In patients with up to three brain metastases and KPS ≥70, adding SRS to WBRT improves functional independence and reduces steroid requirements at six months (Level 1b).

Patients with more than three brain metastases were not included in these trials. Moreover, it is recognised that the number of brain metastases detected on magnetic resonance imaging (MRI) is technique dependent. For small-volume disease, a prospective observational study (Level 2+) in patients with up to ten metastases (largest <10 centimetres³ [cm³], total volume ≤15 cm³) has suggested that overall survival is equivalent for patients with five to ten as compared to two to four metastases and therefore the number of metastases treated using SRS without WBRT may not correlate with outcome. Several retrospective studies (Level 3) have shown that the total volume of brain metastases correlates better with outcomes, including local control, distant intracranial relapse and overall survival after SRS than number of brain metastases.
Recommendations

**Solitary metastases:**

**Surgery or SRS:**

Lesion diameter

- <20 millimetres (mm) – 24 Gy single dose (Grade B)
- 21–30 mm – 18 Gy single dose (Grade B)
- 31–40 mm – 15 Gy single dose (Grade B)

**Multiple metastases up to total volume of 20 cm³ with good performance status (Karnofsky Performance Status ≥70) and controlled extra-cranial disease:**

**SRS:**

Lesion diameter

- <20 mm – 24 Gy single dose (Grade C)
- 21–30 mm – 18 Gy single dose (Grade C)
- 31–40 mm – 15 Gy single dose (Grade C)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.

**Whole-brain radiotherapy with SRS**

While WBRT was part of the initial treatment of patients in the above-mentioned trials of surgery or SRS, three randomised trials have now investigated the addition of WBRT to surgery or SRS for patients with one to four brain metastases. A meta-analysis of these trials has also been published. Adding WBRT to local therapy by surgery or SRS appears to improve intracranial control and reduce neurological deaths without influencing overall survival (Level 1a). However, the addition of WBRT to SRS has been shown in one small randomised trial to result in a significantly greater risk of neurocognitive deficits at three months, and for this reason many groups now choose to defer WBRT. Post-treatment MRI surveillance was used in all three trials and is recommended by some expert groups, but high-level evidence about the value of MRI surveillance is lacking. Avoidance of the hippocampus has been suggested as a method to limit the neurocognitive effects of WBRT, but as yet there is little data to support this.

**Recommendation**

**WBRT with SRS:**

30 Gy in 10 fractions over 2 weeks (Grade A)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.

**Adjuvant postoperative SRS and hypofractionation**

While WBRT reduces the risk of intra-cranial relapse postoperatively, the lack of impact on overall survival has led to the exploration of SRS to the stereotactic cavity. In line
Radiotherapy dose fractionation

Third edition

with previous data, radiotherapy after surgery reduces the risk of intra-cranial relapse, and radiotherapy restricted to the tumour bed appears to be non-inferior to whole brain radiotherapy.\textsuperscript{28,29} However, technical problems and optimal dose and fractionation schedules are as yet unclear. For patients with larger metastases >2 cm diameter, there has been interest in hypofractionated SRS, delivered as 3–5 fractions. As yet, there is no data to support an optimal dose-fractionation schedule.

**Whole-brain radiotherapy for multiple metastases**

**Background**

Several randomised trials have compared different radiotherapy regimens for patients with multiple cerebral metastases. Most have used 30 Gy in ten fractions as the control arm and have compared this regimen to either higher or lower doses.\textsuperscript{30–33} Only one small study of 70 patients has compared the six-month survival rate after 30 Gy in ten fractions to that after 20 Gy in five fractions. There was no significant difference.\textsuperscript{28} A Radiation Therapy Oncology Group (RTOG) study reported in 1980 compared three regimens: 40 Gy in 15 fractions; 30 Gy in ten fractions; and 20 Gy in five fractions.\textsuperscript{34} The median survival in all three groups was between 3.2 months and 3.5 months (\(P>0.05\)). There is, therefore, no clear evidence that 20 Gy in five fractions is inferior to, or better than, 30 Gy in ten fractions (Level 1b).\textsuperscript{16}

Other regimens assessed in RTOG randomised trials included: 10 Gy single-dose and 30–40 Gy in 10–20 fractions; 40 Gy in 20 fractions; 40 Gy in 15 fractions; 30 Gy in 15 fractions and 30 Gy in ten fractions.\textsuperscript{34,35} There was no statistically significant difference in median survival. The trial results suggest that regimens using only one or two fractions are inferior to 30 Gy in ten fractions, but that there is no improvement in survival when dose is increased beyond 30 Gy in ten fractions (Level 1b).\textsuperscript{16}

Patients in RPA Class III have such a poor prognosis that it may be difficult to justify any radiation treatment at all. Careful consideration should be given to patients with non-small cell lung cancer. The Medical Research Council (MRC) QUARTZ study shows no significant benefit in terms of survival or quality adjusted life years for WBRT over optimal supportive care.\textsuperscript{36}

**Recommendation**

**Multiple cerebral metastases:**

- 30 Gy in 10 fractions over 2 weeks (Grade A)
- 20 Gy in 5 fractions over 1 week (Grade A)

The types of evidence and the grading of recommendations used within this review are based on those proposed by the Oxford Centre for Evidence-based Medicine.\textsuperscript{16}


References


References

